{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:02:45Z","timestamp":1780495365994,"version":"3.54.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020821","name":"Monash University Monash Biomedicine Discovery Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020821","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008671","name":"Bundesverband der Deutschen Industrie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.lfs.2026.124472","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T23:29:15Z","timestamp":1779492555000},"page":"124472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart disease"],"prefix":"10.1016","volume":"399","author":[{"given":"Ziqiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Ferens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Salimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Widdop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey A.","family":"Gaspari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrishan S.","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2026.124472_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5334\/gh.1288","article-title":"The heart of the world","volume":"19","author":"Di Cesare","year":"2024","journal-title":"Glob. Heart"},{"key":"10.1016\/j.lfs.2026.124472_bb0010","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","article-title":"Cardiac fibrosis","volume":"117","author":"Frangogiannis","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2026.124472_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.matbio.2024.08.008","article-title":"Myocardial fibrosis from the perspective of the extracellular matrix: mechanisms to clinical impact","volume":"134","author":"Lunde","year":"2024","journal-title":"Matrix Biol."},{"key":"10.1016\/j.lfs.2026.124472_bb0020","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ejhf.1055","article-title":"Left ventricular geometry as a major determinant of left ventricular ejection fraction: physiological considerations and clinical implications","volume":"20","author":"Triposkiadis","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.lfs.2026.124472_bb0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41569-021-00646-w","article-title":"Transforming growth factor-beta in myocardial disease","volume":"19","author":"Frangogiannis","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.lfs.2026.124472_bb0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/biom13010173","article-title":"Laboratory and metabolomic fingerprint in heart failure with preserved ejection fraction: from clinical classification to biomarker signature","volume":"13","author":"Palazzuoli","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.lfs.2026.124472_bb0035","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","article-title":"Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status","volume":"160","author":"Ma","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124472_bb0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1574892809666140702111311","article-title":"Blockade of renin angiotensin system in heart failure post-myocardial infarction: what is the best therapy?","volume":"9","author":"Gullo","year":"2014","journal-title":"Recent Pat. Cardiovasc. Drug Discov."},{"key":"10.1016\/j.lfs.2026.124472_bb0045","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/01.HYP.0000171930.00697.2f","article-title":"Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats","volume":"46","author":"Lekgabe","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2026.124472_bb0050","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1749-6632.2008.03780.x","article-title":"Reversal of cardiac fibrosis and related dysfunction by relaxin","volume":"1160","author":"Du","year":"2009","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.lfs.2026.124472_bb0055","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/CIRCRESAHA.113.301646","article-title":"Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts","volume":"113","author":"Parikh","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.lfs.2026.124472_bb0060","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.hrthm.2015.12.030","article-title":"Relaxin suppresses atrial fibrillation in aged rats by reversing fibrosis and upregulating Na-channels","volume":"13","author":"Henry","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.lfs.2026.124472_bb0065","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bph.13529","article-title":"Anti-fibrotic actions of relaxin","volume":"174","author":"Samuel","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124472_bb0070","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bph.13523","article-title":"The actions of relaxin on the human cardiovascular system","volume":"174","author":"Sarwar","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124472_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/srep39604","article-title":"Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes","volume":"7","author":"Ng","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.lfs.2026.124472_bb0080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mce.2019.01.013","article-title":"Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): rationale for future clinical trials","volume":"487","author":"Dschietzig","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.lfs.2026.124472_bb0085","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.drudis.2020.04.014","article-title":"Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target","volume":"25","author":"Bani","year":"2020","journal-title":"Drug Disc. Today"},{"key":"10.1016\/j.lfs.2026.124472_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114884","article-title":"Relaxin as an anti-fibrotic treatment: perspectives, challenges and future directions","volume":"197","author":"Samuel","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124472_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116407","article-title":"Relaxin suppresses atrial fibrillation, reverses fibrosis and reduces inflammation in aged hearts","volume":"227","author":"Romero","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124472_bb0100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/antiox13020163","article-title":"Serelaxin protects H9c2 cardiac myoblasts against hypoxia and reoxygenation-induced damage through acitvation of AMP kinase\/siruin1: further insight into the molecular mechanisms of the cardioprotection of this hormone","volume":"13","author":"Zizi","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.lfs.2026.124472_bb0105","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/ejhf.3551","article-title":"End-organ protective effect of serelaxin in patients hospitalized for heart failure: results of the bimarker substudy of relaxin in acute heart failure-2 (RELAX-AHF-2)","volume":"27","author":"Voors","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.lfs.2026.124472_bb0110","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034067","article-title":"Novel relaxin receptor RXFP1 agonist AZD3427 in the treatment of heart failure: a phase 1a\/b, first-in-human, randomized, single-blind, placebo-controlled study","volume":"13","author":"Connolly","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.lfs.2026.124472_bb0115","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1681\/ASN.2019060597","article-title":"AT1R-AT2R-RXFP1 functional crosstalk in myofibroblasts: impact on the therapeutic targeting of renal and cardiac fibrosis","volume":"30","author":"Chow","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2026.124472_bb0120","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1111\/bph.16019","article-title":"Functional crosstalk between angiotensin receptors (types 1 and 2) and relaxin family peptide receptor 1 (RXFP1): implications for the therapeutic targeting of fibrosis","volume":"181","author":"Samuel","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124472_bb0125","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/HYPERTENSIONAHA.114.03594","article-title":"Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease","volume":"64","author":"Samuel","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2026.124472_bb0130","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox, K.M. on behalf of the EURopean Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.lfs.2026.124472_bb0135","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.lfs.2026.124472_bb0140","first-page":"350","article-title":"Perindopril vs enalapril in patients with systolic heart failure: systematic review and metaanalysis","volume":"14","author":"DiNicolantonio","year":"2014","journal-title":"Ochsner J."},{"key":"10.1016\/j.lfs.2026.124472_bb0145","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1007\/s12325-023-02641-8","article-title":"Comparing cardiovascular outcomes and costs of perindopril-, enalapril- or losartan-based antihypertensive regimens in South Africa: real-world medical claims database analysis","volume":"40","author":"Snyman","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.lfs.2026.124472_bb0150","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/00005344-200210000-00018","article-title":"Lower risk of postinfarct rupture in mouse heart overexpressing beta 2-adrenergic receptors: importance of collagen content","volume":"40","author":"Gao","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124472_bb0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1042\/CS20070365","article-title":"Higher levels of collagen and facilitated healing protect against ventricular rupture following myocardial infarction","volume":"115","author":"Fang","year":"2008","journal-title":"Clin. Sci."},{"key":"10.1016\/j.lfs.2026.124472_bb0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2017-000298","article-title":"Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010","volume":"2","author":"Bots","year":"2017","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.lfs.2026.124472_bb0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1152\/physiolgenomics.00071.2010","article-title":"Influence of genetic background on ex vivo and in vivo cardiac function in several commonly used inbred mouse strains","volume":"42A","author":"Barnabei","year":"2010","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.lfs.2026.124472_bb0170","doi-asserted-by":"crossref","DOI":"10.35534\/fibrosis.2023.10006","article-title":"The severity of isoproterenol-induced myocardial fibrosis and related dysfunction in mice is strain-dependent","volume":"1","author":"Wang","year":"2023","journal-title":"Fibrosis"},{"key":"10.1016\/j.lfs.2026.124472_bb0175","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1111\/bph.15428","article-title":"Simultaneous targeting of oxidative stress and fibrosis reverses cardiomyopathy-induced ventricular remodelling and dysfunction","volume":"178","author":"Wang","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124472_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114370","article-title":"The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy","volume":"160","author":"Alam","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2026.124472_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112256","article-title":"Comparing the renoprotective effects of BM-MSCs versus BM-MSC-exosomes, when combined with an anti-fibrotic drug, in hypertensive mice","volume":"144","author":"Li","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2026.124472_bb0190","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1440-1681.2011.05572.x","article-title":"Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart","volume":"38","author":"Campbell","year":"2011","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.lfs.2026.124472_bb0195","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/labinvest.2010.198","article-title":"Relaxin remodels fibrotic healing following myocardial infarction","volume":"91","author":"Samuel","year":"2011","journal-title":"Lab. Invest."},{"key":"10.1016\/j.lfs.2026.124472_bb0200","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/art.24380","article-title":"Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial","volume":"60","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.lfs.2026.124472_bb0205","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ajodo.2011.07.024","article-title":"A randomized, placebo-controlled clinical trial on the effects of recombinant human relaxin on tooth movement and short-term stability","volume":"141","author":"McGorray","year":"2012","journal-title":"Am. J. Orthod. Dentofacial Orthop."},{"key":"10.1016\/j.lfs.2026.124472_bb0210","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s13063-020-4203-9","article-title":"A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)","volume":"21","author":"Gifford","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.lfs.2026.124472_bb0215","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1021\/acsptsci.9b00095","article-title":"Serelaxin and the AT(2) receptor agonist CGP42112 evoked a similar, nonadditive, cardiac antifibrotic effect in high salt-fed mice that were refractory to candesartan cilexetil","volume":"3","author":"Wang","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.lfs.2026.124472_bb0220","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/bph.14666","article-title":"Serelaxin enhances the therapeutic effects of human amnion epithelial cell-derived exosomes in experimental models of lung disease","volume":"176","author":"Royce","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2026.124472_bb0225","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1681\/ASN.V3101643","article-title":"Angiotensin II receptor subtypes in the kidney","volume":"3","author":"Edwards","year":"1993","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2026.124472_bb0230","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/ki.1994.426","article-title":"Pharmacology of angiotensin II receptors in the kidney","volume":"46","author":"de Gasparo","year":"1994","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2026.124472_bb0235","doi-asserted-by":"crossref","first-page":"31S","DOI":"10.1016\/S0895-7061(99)00249-6","article-title":"Localization and function of angiotensin AT1 receptors","volume":"13","author":"Allen","year":"2000","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.lfs.2026.124472_bb0240","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0167-5273(90)90005-P","article-title":"In vitro autoradiographic localization of binding to angiotensin receptors in the rat heart","volume":"28","author":"Allen","year":"1990","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.lfs.2026.124472_bb0245","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1161\/01.CIR.95.5.1201","article-title":"AT1 and AT2 angiotensin receptor gene expression in human heart failure","volume":"95","author":"Haywood","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2026.124472_bb0250","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.physbeh.2013.01.013","article-title":"Angiotensin-converting enzyme inhibition reduces food intake and weight gain and improves glucose tolerance in melanocortin-4 receptor deficient female rats","volume":"121","author":"Mul","year":"2013","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.lfs.2026.124472_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.682726","article-title":"Inhibition of the renin-angiotensin system reduces gene expression of inflammatory mediators in adipose tissue independent of energy balance","volume":"12","author":"Mitchell","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.lfs.2026.124472_bb0260","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1161\/01.HYP.37.3.974","article-title":"Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene","volume":"37","author":"Peng","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.lfs.2026.124472_bb0265","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1042\/cs1040109","article-title":"Effects of angiotensin II receptor blockade versus angiotensin-converting-enzyme inhibition on ventricular remodelling following myocardial infarction in the mouse","volume":"104","author":"Patten","year":"2003","journal-title":"Clin. Sci."},{"key":"10.1016\/j.lfs.2026.124472_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110824","article-title":"Combination of LCZ696 and ACEi further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice","volume":"133","author":"Liu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2026.124472_bb0275","doi-asserted-by":"crossref","first-page":"H3057","DOI":"10.1152\/ajpheart.00447.2006","article-title":"Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure","volume":"292","author":"Brower","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.lfs.2026.124472_bb0280","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.yjmcc.2007.09.002","article-title":"ACE inhibitors to block MMP-9 activity: new functions for old inhibitors","volume":"43","author":"Jin","year":"2007","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.lfs.2026.124472_bb0285","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1523-1755.2005.00384.x","article-title":"The anti-fibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway","volume":"68","author":"Heeg","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.lfs.2026.124472_bb0290","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1096\/fj.08-120857","article-title":"Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2","volume":"23","author":"Mookerjee","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.lfs.2026.124472_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042714","article-title":"Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS","volume":"7","author":"Chow","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2026.124472_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063896","article-title":"Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-beta\/Smad3 signaling","volume":"8","author":"Sassoli","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2026.124472_bb0305","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cardiores.2006.10.002","article-title":"The role of TGF-beta signaling in myocardial infarction and cardiac remodeling","volume":"74","author":"Bujak","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.lfs.2026.124472_bb0310","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1210\/en.2008-0250","article-title":"Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy","volume":"149","author":"Samuel","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.lfs.2026.124472_bb0315","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yexcr.2017.10.004","article-title":"Serelaxin inhibits differentiation and fibrotic behaviors of cardiac fibroblasts by suppressing ALK-5\/Smad2\/3 signaling pathway","volume":"362","author":"Wu","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.lfs.2026.124472_bb0320","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s13287-024-03992-x","article-title":"The renoprotective efficacy and safety of genetically-engineered human bone marrow-derived mesenchymal stromal cells expressing anti-fibrotic cargo","volume":"15","author":"Li","year":"2024","journal-title":"Stem Cell Res. Ther."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052600281X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052600281X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:02:01Z","timestamp":1780491721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002432052600281X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":64,"alternative-id":["S002432052600281X"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124472","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart disease","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2026.124472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"124472"}}